Renaissance Technologies’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

Renaissance Technologies’s Portfolio VAXX Stock Details VAXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-35,100	Closed	-$25K	–	4096
2024 Q1	$25K	Buy	+35,100	New	+$25.4K	﹤0.01%	3572
2023 Q1	–	Sell	-107,594	Closed	-$151K	–	4495
2022 Q4	$151K	Sell	107,594 -76,041	-41%	-$128K	﹤0.01%	3510
2022 Q3	$364K	Sell	183,635 -78,765	-30%	-$164K	﹤0.01%	3104
2022 Q2	$412K	Buy	+262,400	New	+$992K	﹤0.01%	3272

Other funds holding VAXX

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

CGL

Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Robinswood Financial Kirkland, Washington $349M AUM 14.9% 1-Year Est. Return

Renaissance Technologies's VAXX Position: Q2 2024 in Review

Renaissance Technologies sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q2 2024, closing a stake of 35,100 shares — an estimated $25K sold.

Renaissance Technologies first reported a position in VAXX in Q2 2022 and held it in 4 quarters. The position peaked at $412K in Q2 2022. 8 funds tracked by Wall St. Rank hold VAXX as of Q2 2024.

Renaissance Technologies reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q2 2024 after selling out during the quarter.
Renaissance Technologies sold 35,100 Vaxxinity, Inc. Class A Common Stock shares in Q2 2024, an estimated $25K.
Renaissance Technologies first reported a position in Vaxxinity, Inc. Class A Common Stock in Q2 2022 and held it in 4 quarters.
Renaissance Technologies's Vaxxinity, Inc. Class A Common Stock position peaked at $412K in Q2 2022.
8 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.